Erlonat 150 mg - Erlotinib Natco tablet Price, Cost India.
Erlonat 150mg
Drug profile
Erlonat is a Natco pharma item which is containing a functioning substance known as Erlotinib, a first line medication of decision in metastatic phase of non little cell lung tumor.Erlonat 150mg is normally endorsed for the patients who are not counters to less than one chemotherapy regimen.
Erlonat is pharmacologically arranged as tyrosine kinase inhibitor.
Erlonat 150mg is altogether raising the serum aminotransferase levels amid the treatment and this may causes liver wounds.
Erlonat 150mg tablets are containing 150mg of Erlotinib as a hostile to tumor specialist.
 |
| Erlonat 150mg |
PRODUCT DETAILS
Brand name: ErlonatActive constituent: Erlotinib
Strength: 150MG
Mfg: Natco pharma
Pack: 30 tablets per container
Category: Anti-neoplastic agent
Prescribing information of Erlonat ;
Before starting therapy with Erlonat 150mg, determination of mutation status is necessary for the patients to prevent the conditions like false positive or negative assessment.
Non small cell lung cancer:
Erlonat tablets are indicated primarily for the treatment of advanced NSCLC, in patients who are containing exon 19 deletions or 21substitution mutations.Erlonat 150mg tablets are also considered as monotherapy for the advanced NSCLC patients who are progressive after 4 weeks of therapy with platinum based compounds.
Erlonat is mainly indicated for the patients who are not responding for one chemotherapy drugs.
But the potency of Erlonat 150mg has not been evaluated, for first line treatment in advanced NSCLC exon 19 deletions or mutations.
Mechanism of Erlonat
Erlonat has Erlotinib dynamic substance comprising hostile to neoplastic action with tyrosine kinase denying impact.Erlonat 150mg displays hostile to tumor action by following up on cell surface in which the EGFR presents.
Erlonat mediates with EGFR phosphorylation which is brings about cell lyses.
Erlonat is likewise engaged with blockage of EFGR related flag exchange which is contributed for cell development.
Absorption
Nearly 60% of Erlotinib get absorbed after oral administration of Erlonat 150mg tablets.The oral bioavailability reaches nearly 100%
In case of co administration of Erlonat tablets with gastric regulators like proton pump inhibitors causes depletion of Erlotinib exposure and leads to increase its concentration.
Distribution
Approximately 93% of Erlotinib get binds to human plasma protein.The apparent volume of distribution is 232L.
Excretion
The mean creatinine clearance value 4.47L/hrWhen to take the Erlonat 150mg tablets
Erlonat tablets should be administered on an empty stomach; it should be taken at least 1 hour earlier or 2 hours after food intake.
If patients not getting severe rashes, then therapy with Erlonat should be continue.
In combinational therapy of Erlonat 150mg with CYP3A4 substrates or modulators, dosage alteration is necessary for up to 50mg.
Dose modification;
In pulmonary symptoms like cough, dyspnea, fever conditions; Erlonat 150mg tablets treatment should be postpones.In case of dose reduction is required for the patients, Erlonat dose may reduced to 50mg
Erlonat caused side effects
The most common adverse effects occurred in this therapy such as;
Severe diarrheaRashes
Interstitial lung disease
In NSCLC:
Anorexia
Fatigue
Dry skin
Conjunctivitis
Drug -drug interaction
Erlotinib should not be combined with platinum based compounds; it may increases the effect of concentration of platinum based compounds.Erlonat 150mg should not be concomitant with Capecitabine; it may causes elevation of effect of concentration of Erlotinib.
Proteasome prohibitor like Bortezomib may be conventionally significant the effect of EFGR inhibitors including Erlonat
Erlonat tablets are strong inhibitor of CYP1A1, moderate inhibitor of CYP3A4 & CYP2C8 and also potent inhibitor of Glucuronidation by UGT1A1.
Erlonat tablet co administered with CYP3A4 inducers like rifampicin causes decreasing the exposure of Erlonat . Some CYP3A4 inducers like rifabutin, rifapentine, anti-convulsants.
Cigarette smoking is occurs during the therapy with Erlonat 150mg , leads to decreasing the exposure to Erlonat 150mg.
Erlonat solubility is occurs by pH values, once pH decreases solubility of Erlotinib get increases and causes loss of effects.
Erlonat should not be co administered with gastric regulators at a time; some time intervals like around 2 hours should be taken before or after ingestion of food.
Food drug interaction
Erlonat 150mg tablets should be taken on an empty stomach; because pH regulates the solubility of Erlotinib.Avoid intake of grape fruit or juice during therapy with Erlotinib.
This may results as elevating the Erlotinib levels in the body leads to causes adverse effects.
Possible contraindications
Any anaphylactic reactions like rashes, Stevens Johnson syndrome may occur during the therapy due to the patients are contraindicated to the component of Erlonat .Safety measures
1.Pulmonary toxicities:
Interstitial lung disease may occur to overcome this effect by interrupt or discontinue the treatment with Erlonat .Patient may frequently examine by undergone ILD analysis; this may occur in combinational therapy with gemcitabine.
2.Renal damage:
Some renal disorders may occur, to avoid this problem postpone or discontinue the theory with Erlonat tablets and follow the regular renal function test.3.Hepatic failure:
Due to increasing levels of bilirubin, AST & ALT causes liver toxicity, to prevent this effect monitor the patients with frequent hepatic function test.In severe condition, treatment should be stopped.
4.Diarrhea:
Providing rehydration due to loss of fluids and also give loperamide as a alternative drug.In severity, discontinue the therapy with Erlonat 150mg.
5.GI perforations:
This may occur due to concurrent use of Erlonat with NSAIDS, corticosteroids, anti-angiogenic agents, or taxane based compounds causes GI perforation by increasing the acid levels in stomach.This may overcome by discontinuing the treatment.
7.Cardiac disorders:
Myocardial infarction may occur due to combination of Erlonat with gemcitabine, to avoid this problem stop the combinational therapy.Pregnancy and lactation
Pregnancy category D
Erlotinib Erlonat 150mg causes fetal harm; it should not be suggested in pregnancy condition.Breast feeding should not be allowed.
Storage and handling
Erlonat 150mg tablet container should be stored at 25oC.The container should be keep away from heat, light & moisture.
Over dosage
Missed dose is the one of the reason for obtaining over dosage condition.Once over dosage of Erlonat occurs in patients, must provided with supportive measures and follow the preventive measures
The over dosage of Erlotinib causes severe diarrhea & rashes, elevating AST, ALT leads to liver damage.
Discontinue the therapy.
Comments
Post a Comment